Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose
Executive Summary
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.
You may also be interested in...
Severe Asthma Market Snapshot: A Competitive Therapy Area That Will Test Payers' Influence
Several biologic drugs are now available for the 10% of asthma patients with severe uncontrolled disease, and Dupixent could join them later this year, setting the therapy area up for a competitive showdown.
Severe Asthma Market Snapshot: A Competitive Therapy Area That Will Test Payers' Influence
Several biologic drugs are now available for the 10% of asthma patients with severe uncontrolled disease, and Dupixent could join them later this year, setting the therapy area up for a competitive showdown.
Dupixent FDA Asthma Review Bolsters Sanofi And Regeneron
Already approved for atopic dermatitis, the partners have got a PDUFA date of Oct. 20 which could expand the label on their interleukin-4 and -13 inhibitor to include asthma.